Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing, and treating HIV
First Claim
Patent Images
1. An isolated peptide with antiviral efficacy consisting of the amino acid sequence of SEQ ID NO:
- 1, said peptide having substantial in vitro binding affinity for human immunodeficiency virus type-1 (HIV-1), gp 120, HIV-1 gp 41 and HIV-1 infected human CD4 cells.
1 Assignment
0 Petitions
Accused Products
Abstract
An isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.
17 Citations
7 Claims
-
1. An isolated peptide with antiviral efficacy consisting of the amino acid sequence of SEQ ID NO:
- 1, said peptide having substantial in vitro binding affinity for human immunodeficiency virus type-1 (HIV-1), gp 120, HIV-1 gp 41 and HIV-1 infected human CD4 cells.
- View Dependent Claims (3, 4, 5, 6, 7)
-
2. A composition including a carrier and a peptide with antiviral efficacy, said peptide consisting of the amino acid sequence of SEQ ID NO:
- 1 and having substantial in vitro binding affinity for HIV-1 gp 120, HIV-1 gp41 and HIV-1 infected human CD4 cells.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeThe Zhabilov Trust
-
Original AssigneeThe Zhabilov Trust
-
InventorsZhabilov, Harry H.
-
Primary Examiner(s)Campell; Bruce
-
Assistant Examiner(s)LI, BAO Q
-
Application NumberUS11/177,427Publication NumberTime in Patent Office1,289 DaysField of Search530/300US Class Current530/327CPC Class CodesA61K 38/10 Peptides having 12 to 20 am...A61P 31/18 for HIVC07K 14/47 from mammalsC07K 7/06 having 5 to 11 amino acidsG01N 2333/16 HIV-1, HIV-2
